2022
Microtentacle Formation in Ovarian Carcinoma
Reader JC, Fan C, Ory EC, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM. Microtentacle Formation in Ovarian Carcinoma. Cancers 2022, 14: 800. PMID: 35159067, PMCID: PMC8834106, DOI: 10.3390/cancers14030800.Peer-Reviewed Original ResearchHuman ovarian surface epitheliumOvarian cancerCell linesCancer cellsMajor therapeutic challengeIntraperitoneal drug deliveryOvarian surface epitheliumOvarian cancer metastasisNew therapeutic targetsDevelopment of chemoresistanceEffect of treatmentBreast cancer cellsOSC cell linesExtrapelvic metastasesMalignant ascitesTherapeutic challengeOvarian carcinomaSurface epitheliumTherapeutic targetMetastatic potentialAscitesCancer metastasisΒ-tubulin isotypesIndividual cancer cellsMetastasis
2018
MicroRNA signatures discriminate between uterine and ovarian serous carcinomas
Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinomaDiagnosis, DifferentialFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansMicroRNAsMiddle AgedNeoplasm GradingNeoplasms, Cystic, Mucinous, and SerousOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPhenotypePredictive Value of TestsReproducibility of ResultsRetrospective StudiesTranscriptomeUterine NeoplasmsConceptsHigh-grade serous carcinomaOvarian serous carcinomaSerous carcinomaOvarian malignancyPrimary ovarian high-grade serous carcinomaOvarian high-grade serous carcinomaMiRNA signatureEndometrial serous carcinomaHigh-grade ovarian serous carcinomaUterine serous carcinomaEndometrial counterpartOvarian primaryTaqMan Low Density Array technologySynchronous primariesEndometrial cancerMetastatic tumorsCarcinomaPrimary siteSignature panelPathological determinationMicroRNA signatureSignificant discriminatory powerCancer cellsMalignancyLineage characteristics
2017
Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells
Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics 2017, 16: 323-333. PMID: 27956521, PMCID: PMC5292071, DOI: 10.1158/1535-7163.mct-16-0501.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalDisease Models, AnimalDrug CarriersDrug Delivery SystemsDrug Resistance, NeoplasmEnterotoxinsFemaleGene ExpressionGene Transfer TechniquesGenes, Transgenic, SuicideGenetic TherapyHumansMiceNanoparticlesOvarian NeoplasmsPromoter Regions, GeneticTumor BurdenXenograft Model Antitumor AssaysConceptsOvarian cancer cellsClostridium perfringens enterotoxinChemotherapy-resistant ovarian cancer cellsIntraperitoneal injectionCancer cellsMultiple intraperitoneal injectionsOvarian cancer xenograftsOvarian tumor cell linesLethal gynecologic cancerTumor-bearing miceOvarian cancer cell deathVivo biodistribution studiesGene therapySuicide gene therapyGynecologic cancerCancer xenograftsOvarian cancerCancer cell deathTherapeutic approachesControl nanoparticlesTumor growthTumor cell linesClaudin-3Biodistribution studiesTumor cells
2016
Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers
Menderes G, Hicks C, Black JD, Schwab CL, Santin AD. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. Expert Opinion On Biological Therapy 2016, 16: 989-1004. PMID: 27070175, DOI: 10.1080/14712598.2016.1177018.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCytotoxic T-lymphocyte antigen-4Checkpoint inhibitorsGynecologic cancer patientsGynecologic cancerCancer patientsImmune responseT-lymphocyte antigen-4Non-gynecologic cancersEffective cancer immunotherapyLong-term remissionCheckpoint inhibitor immunotherapySurvival of patientsCancer cellsImmunotherapeutic researchAnticancer immunityPD-1Advanced cancerImmunotherapeutic agentsTreatment regimensAntigen-4Cancer immunotherapyClinical activityClinical experienceImmunotherapy
2015
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery
Romani C, Cocco E, Bignotti E, Moratto D, Bugatti A, Todeschini P, Bandiera E, Tassi R, Zanotti L, Pecorelli S, Sartori E, Odicino FE, de Marco A, Santin AD, Ravaggi A, Mitola S. Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. Oncotarget 2015, 6: 34617-34628. PMID: 26416446, PMCID: PMC4741477, DOI: 10.18632/oncotarget.5315.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeoplasmAntibody AffinityAntineoplastic AgentsBlotting, WesternCell Line, TumorClaudin-3Drug CarriersDrug Delivery SystemsEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHumansImmunoglobulin GMiceMice, SCIDMicroscopy, ConfocalMicroscopy, FluorescenceOvarian NeoplasmsReal-Time Polymerase Chain ReactionRNA, Small InterferingSurface Plasmon ResonanceTransfectionXenograft Model Antitumor AssaysConceptsClostridium perfringens enterotoxinTumor cellsActive anti-cancer compoundsHuman IgG1 Fc domainHuman ovarian cancer cell linesOvarian cancer cell linesOvarian cancer patientsOvarian carcinoma xenograftsOvarian cancer cellsIgG1 Fc domainCancer cell linesAggressive tumorsCancer patientsCarcinoma xenograftsOncological settingIgG1 antibodiesClaudin3Anti-cancer compoundsChimeric antibodyAntitumor efficacySelective drug deliveryPerfringens enterotoxinCancer cellsAntibodiesFc domainClostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers
Black JD, Lopez S, Cocco E, Schwab CL, English DP, Santin AD. Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers. Toxins 2015, 7: 1116-1125. PMID: 25835384, PMCID: PMC4417958, DOI: 10.3390/toxins7041116.Peer-Reviewed Original ResearchConceptsClostridium perfringens enterotoxinClaudin-3Claudin-4Perfringens enterotoxinAggressive human cancer cellsGynecologic malignanciesGynecologic cancerHuman cancer cellsOperative settingHuman tumorsCancer cellsPotential roleTumorsSurface proteinsEnterotoxinTreatmentHigh affinitySurgeryMalignancyCancerCytolysisReceptors
2012
Mammaglobin B (SCGB2A1)-specific CD8+ cytotoxic T lymphocytes (CTL) are highly effective in killing autologous chemotherapy resistant ovarian cancer cells: Implications for SCGB2A1 dendritic cell-based therapeutic vaccines
Roque D, Bellone S, Betti M, Silasi D, Ratner E, Azodi M, Schwartz P, Rutherford T, Pecorelli S, Santin A. Mammaglobin B (SCGB2A1)-specific CD8+ cytotoxic T lymphocytes (CTL) are highly effective in killing autologous chemotherapy resistant ovarian cancer cells: Implications for SCGB2A1 dendritic cell-based therapeutic vaccines. Gynecologic Oncology 2012, 125: s34. DOI: 10.1016/j.ygyno.2011.12.078.Peer-Reviewed Original Research
2011
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation
Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, DiMaio D. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 2011, 422: 114-124. PMID: 22056390, PMCID: PMC3229657, DOI: 10.1016/j.virol.2011.10.012.Peer-Reviewed Original ResearchConceptsCervical carcinoma cellsCervical cancer cellsHuman papillomavirus E6Human cervical carcinoma cellsCarcinoma cellsPrimary cervical cancer cellsCancer cellsPapillomavirus E6Cervical carcinoma cell linesE2 proteinHuman cervical cancer cellsCarcinoma cell linesE7 expressionE7 oncogenesLow passage numberSerum-free conditionsCell surface receptorsSV40 infectionTumor suppressor pathwayCell linesPrimary cellsViral vectorsE6Suppressor pathwayPassage number
1998
Effects of Retinoic Acid Combined with Irradiation on the Expression of Major Histocompatibility Complex Molecules and Adhesion/Costimulation Molecules ICAM-1 in Human Cervical Cancer
Santin A, Hermonat P, Ravaggi A, Chiriva-Internati M, Hiserodt J, Pecorelli S, Parham G. Effects of Retinoic Acid Combined with Irradiation on the Expression of Major Histocompatibility Complex Molecules and Adhesion/Costimulation Molecules ICAM-1 in Human Cervical Cancer. Gynecologic Oncology 1998, 70: 195-201. PMID: 9740690, DOI: 10.1006/gyno.1998.5060.Peer-Reviewed Original ResearchConceptsIntercellular adhesion molecule-1Class II surface antigensICAM-1 antigenSurface antigenMHC class ICervical cancer cellsClass IRetinoic acidCervical cancerHigh dosesUpregulated HLA class ITumor cellsSiHa cervical cancer cellsMajor histocompatibility complex class ICancer cellsHistocompatibility complex class IMajor histocompatibility complex moleculesMolecules ICAM-1Adhesion molecule-1HLA class IICAM-1 moleculesUntreated tumor cellsHuman cervical cancerCervical cancer therapyComplex class I